Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samuelsson, J
Right arrow Articles by Pahl, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samuelsson, J
Right arrow Articles by Pahl, H.
Haematologica, Vol 91, Issue 9, 1281-1282
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial, Phase II

Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia

J Samuelsson, M Mutschler, G Birgegard, P Gram-Hansen, M Bjorkholm, and HL Pahl

Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.


This article has been cited by other articles:


Home page
 haematolHome page
A. Ricksten, L. Palmqvist, P. Johansson, and B. Andreasson
Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia
Haematologica, August 1, 2008; 93(8): 1260 - 1261.
[Full Text] [PDF]

Home page
 haematolHome page
G. Helbig, B. Stella-Holowiecka, M. Majewski, M. Lewandowska, and J. Holowiecki
Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation
Haematologica, November 1, 2007; 92(11): e118 - e119.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Finazzi and T. Barbui
How I treat patients with polycythemia vera
Blood, June 15, 2007; 109(12): 5104 - 5111.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.